Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant, Boston Scientific Stocks Weather DES Issues

This article was originally published in The Gray Sheet

Executive Summary

Guidant's July 1 confirmation that design changes to its Champion everolimus drug-eluting stent will only delay a launch by six to eight months appears to have partially allayed investor concerns after an initial stock sell-off in May
Advertisement

Related Content

Guidant Strengthens Resolve To Build Vulnerable Plaque Market
Guidant Champion Stent Design Flaw Delays Marketing By Up To Eight Months
Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes
Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes
Boston Scientific To Study Complex DES Use; Taxus Complaints Surface
AMO Adds Glaucoma Device, Fills Cataract Line With $450 Mil. Pfizer Eye Unit
Cypher Warning Letter Cites Systemic GMP Problems At Multiple Facilities
Guidant/DoJ Probe Details Postmarket Reporting Meltdown With AAA Device
Advertisement
UsernamePublicRestriction

Register

MT020538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel